CPIX Cumberland Pharmaceuticals Inc.
$4.87▼ -1.62%
Healthcare
Other
Volume 141.3K
Avg Volume (10D) 172.2K
Key Metrics & Fundamentals
Market Cap
$72.97M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.85 - 9.28
% vs 50 MA
-32.78%
% vs 200 MA
-11.81%
RSI-14
34.5
MACD Histogram
-0.3000
Beta (1Y vs SPY)
0.68
Free Cash Flow
-$1.61M
Gross Rev
$8.80M
Gross Profit
$8.80M
EBITDA
-$3.09M
COGS
–
Operating Exp
$3.33M
Operating Income
$5.47M
EBIT
$5.47M
Pretax Income
-$3.10M
Net Income
-$4.28M
EPS (Diluted)
-0.29
Price & Volume History
Loading chart…
Recent News
Cumberland Pharmaceuticals Begins Rolling FDA NDA for Dyscorban in Duchenne Cardiomyopathy
MarketBeat · Oct 26, 2026 6:02 PM ET
CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM
PR Newswire · Oct 26, 2026 4:40 PM ET
Cumberland Pharmaceuticals stock tumbles on trial results
Investing.com · Oct 23, 2026 5:08 PM ET
Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results
PR Newswire · Oct 23, 2026 4:05 PM ET
CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL
PR Newswire · Oct 23, 2026 9:05 AM ET
CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM
PR Newswire · Oct 19, 2026 4:05 PM ET
Cumberland Pharmaceuticals Inc (CPIX) (Q2 2026) Earnings Call Highlights: Strategic ...
GuruFocus.com · Aug 5, 2026 1:05 AM ET
Cumberland Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · Aug 4, 2026 7:04 PM ET
Cumberland: Q2 Earnings Snapshot
Associated Press · Aug 4, 2026 5:18 PM ET
CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
PR Newswire · Aug 4, 2026 5:06 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See CPIX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.